NCT07459322

Brief Summary

This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
20mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
Apr 2026Dec 2027

First Submitted

Initial submission to the registry

March 4, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 9, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

April 15, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2027

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

March 9, 2026

Status Verified

March 1, 2026

Enrollment Period

1 year

First QC Date

March 4, 2026

Last Update Submit

March 4, 2026

Conditions

Keywords

OSASDISESedationRemimazolamDexmedetomidine

Outcome Measures

Primary Outcomes (6)

  • Apneic events

    Apnea event during sedation

    from start of sedation to outpatient discharge from postoperative care unit

  • Bradycardia

    Heart rate less than 60 beats per minute during sedation

    from start of sedation to outpatient discharge from postoperative care unit

  • Hypotension

    Hypotensive event (defined as less mean blood pressure less than 80% of preoperative mean blood pressure) during sedation

    from start of sedation to outpatient discharge from postoperative care unit

  • Agitation

    Agitation, coughing, involuntary movement during sedation

    from start of sedation to outpatient discharge from postoperative care unit

  • Surgeon satisfaction score

    Rate of surgeon satisfaction of certain sedation

    From start of sedation to outpatient discharge from postoperative care unit

  • Hypoxic event

    hypoxic event during sedation

    From start of sedation to outpatient discharge from postoperative care unit

Secondary Outcomes (2)

  • Top-up requirement

    From start of sedation to outpatient discharge from postoperative care unit

  • Patient satisfaction score

    Before outpatient discharge from postoperative care unit

Study Arms (2)

Patients with OSAS receiving dexmedetomidine for sedation during DISE

ACTIVE COMPARATOR

Patients with obsturctive sleep apne syndrome receiving dexmedetomidine for sedation during drug-induced sleep endoscopy

Drug: Dexmedetomidine

Patients with OSAS receiving remimazolam for sedation during DISE

EXPERIMENTAL

Patients with obsturctive sleep apne syndrome receiving remimazolam for sedation during drug-induced sleep endoscopy

Drug: Remimazolam

Interventions

Patients with obsturctive sleep apne syndrome receiving remimazolam for sedation during drug-induced sleep endoscopy

Patients with OSAS receiving remimazolam for sedation during DISE

Patients with obsturctive sleep apne syndrome receiving dexmedetomidine for sedation during drug-induced sleep endoscopy

Patients with OSAS receiving dexmedetomidine for sedation during DISE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients age \> 18 years old
  • American Society of Ansthesiologists functional class \< III
  • Schedule to receive DISE exam for evaluation of OSAS

You may not qualify if:

  • Patient refusal
  • Allergic to experimental medication
  • History of central nervous system diseases
  • History of psychiatric diseases
  • Pregnancy
  • Severe, uncontrolled systemic diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fu Jen Catholic University Hosptial

New Taipei City, Taiwan (r.o.c.), 24352, Taiwan

Location

Related Publications (5)

  • Cheong CS, Loke W, Thong MKT, Toh ST, Lee CH. The Emerging Role of Drug-Induced Sleep Endoscopy in the Management of Obstructive Sleep Apnea. Clin Exp Otorhinolaryngol. 2021 May;14(2):149-158. doi: 10.21053/ceo.2020.01704. Epub 2020 Oct 16.

    PMID: 33092317BACKGROUND
  • Lucas-Borja ME, Zema DA, Fernandez C, Soria R, Miralles I, Santana VM, Perez-Romero J, Del Campo AD, Delgado-Baquerizo M. Limited contribution of post-fire eco-engineering techniques to support post-fire plant diversity. Sci Total Environ. 2022 Apr 1;815:152894. doi: 10.1016/j.scitotenv.2021.152894. Epub 2022 Jan 5.

    PMID: 34998748BACKGROUND
  • Chen YT, Sun CK, Wu KY, Chang YJ, Chiang MH, Chen IW, Liao SW, Hung KC. The Use of Propofol versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021 Apr 9;10(8):1585. doi: 10.3390/jcm10081585.

    PMID: 33918644BACKGROUND
  • Yan L, Wang X, Chen Z, Wu N, Li H, Yang B. Safety and efficacy of remimazolam tosilate combined with low-dose fentanyl for procedural sedation in obese patients undergoing gastroscopy: study protocol for a single-centre, double-blind, randomised controlled trial. BMJ Open. 2023 Dec 28;13(12):e079095. doi: 10.1136/bmjopen-2023-079095.

    PMID: 38154891BACKGROUND
  • Xin Y,Lu P,Guan S,Si S,Sun R,Xia W,Xu H

    BACKGROUND

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Interventions

remimazolamDexmedetomidine

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Chao Hsien Sung, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2026

First Posted

March 9, 2026

Study Start

April 15, 2026

Primary Completion (Estimated)

April 15, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

March 9, 2026

Record last verified: 2026-03

Locations